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Abstract: The treatment options for facial rejuvenation using dermatological, nonsurgical 
techniques have dramatically increased in the past 10 years. This follows the introduction of 
botulinum toxin and a variety of dermal ﬁ  llers. The public interest in noninvasive treatments has 
changed the market beyond recognition with more physicians involved in providing services to 
satiate the demand. The impact on the public and medical profession is discussed.
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Introduction
Deﬁ  nition of facial rejuvenation
This review is concerned with the concept of facial rejuvenation utilizing dermatological 
preparations in a nonsurgical approach. The combination of art and science now provides 
physicians with the capability to make the face appear more youthful. Facial aging com-
bines intrinsic or genetically determined and extrinsic factors including sun exposure, 
smoking, diet, and general lifestyle. The features of the aging face are well described 
and include loss of skin elasticity, lines, wrinkles and dyspigmentation. The management 
options are focused on moderating and even reversing some of these changes
The market
There are few reliable statistics in the UK. A Mintel™ report1 stated the number of 
cosmetic surgery operations in the UK in value terms had increased from £450 million 
in 2005 to £900 million in 2007, a 100% increase over three years. In 2005, this included 
230,000 nonsurgical procedures such as Botox™ and ﬁ  llers which rose to 472,000 
in 2007. In the UK, the British Association of Aesthetic Plastic Surgeons (BAAPS)2 
produces reliable cosmetic surgery ﬁ  gures but they only relate to its members. It is 
not known what percentage they form of the total number of UK procedures. In 2007, 
they performed 32,453 procedures, 12.2% up on 2006.
In the US, there are more reliable indicators produced by surgical audits from the 
American Society for Aesthetic Plastic Surgery (ASAPS) (Figure 1).
There were almost 11.7 million cosmetic procedures in the US in 2007, of which 18% 
were surgical and 82% nonsurgical. From 1997 to 2007, surgical procedures increased 
by 114% and nonsurgical by 754%. However in the year 2006–2007 there was only a 
2% overall increase. The dramatic increases occurred between 1997 and 2004 with a 
leveling off in the past four years (Figure 2). Women account for 91% of procedures, but 
signiﬁ  cantly men had a year of increase of 17% from 2006. In nonsurgical care, the main 
procedures were: Botox™ 23%, dermal ﬁ  llers 18%, and laser hair removal 14.6%.
Inﬂ  uences in the market
The main forces in the market place are the written media, TV shows, radio, and celebrity 
endorsement and peer pressure. There are many sociological and psychological factors Clinical Interventions in Aging 2009:4 82
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that inﬂ  uence individual choices, which are beyond the remit 
of this review. Magazines often include features on cosmetic 
work with prominence given to “celebrities” which may have 
an inﬂ  uence on public opinion. In the UK, television series 
such as “10 Years Younger” and “Extreme Makeover” have 
brought into the comfort of our homes vivid illustrations of 
how the worst possible cases can be transformed. Women 
and men are under pressure to appear youthful and healthy. 
High separation and divorce rates, peers, work and career 
prospects all have a signiﬁ  cant inﬂ  uence. The increased public 
awareness and the Internet are probably the most important 
features driving the market forwards.
Demand for nonsurgical care
We are at present in the middle of a minimally invasive, 
no downtime, socially convenient, quick recovery, cost-
conscious revolution. The public is seeking easy, pain-free 
methods of appearing youthful and healthy without the 
problems of invasive cosmetic surgery. This demand has 
had signiﬁ  cant impact on:
1.  Suppliers of dermatological preparations and other nonin-
vasive technology. The pressure to produce new innova-
tive products is high which can lead to premature launches 
before there is an opportunity for adequate clinical 
assessment. Unfortunately in the EU the regulations 
relating to the introduction of ﬁ  llers are not demanding. 
This has led to over 70 ﬁ  ller products being currently 
available which causes professional and public confusion. 
At this time in the US where there is a more vigorous regu-
latory approach, there are less then 10 approved ﬁ  llers. 
There are some pharmaceutical companies involved, 
Allergan (Irvine, CA), the manufacturer of Botox™ being 
a major player. They have recently added ﬁ  llers, skincare 
and breast implants to their portfolio. Others are sure to 
follow.
2.  For the medical profession in the UK, there is now 
pressure to ﬁ  nd high standard, independently validated 
training courses. The Royal Colleges in the UK have to 
recognize the public and professional interest and become 
more actively involved in education and training.
3.  Governments need to understand the importance of 
regulation in order to elevate standards and ensure public 
safety.
Differentiation of nonsurgical/surgical care
Up to the 1980s, the famous and privileged were the only 
segments of the population considering cosmetic enhance-
ment. The procedures were limited to surgery and deep acid 
peels. The introduction of wrinkle ﬁ  llers and botulinum 
toxins heralded the onset of the nonsurgical era, providing 
low risk, effective but subtle enhancements.
Present nonsurgical options
Skin care at home
Effective skin care is one of the most neglected areas in 
cosmetic medical practice. Although Doctors have been 
convinced of the beneﬁ  ts of sunscreens and moisturis-
ers, the concept of skin rejuvenation using creams and 
lotions is viewed with a high degree of scepticism. In the 
1980s, Dr Albert Kligman3 induced a radical change of 
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thought by demonstrating that sun-damaged skin could 
be rejuvenated using trans-retinoic acid, a vitamin A 
derivative. This led to Retin A™ being given approval, 
as a topical, prescription only agent, for the treatment of 
sun-damaged skin. This single event triggered incredible 
interest and investment from cosmetic manufacturers and 
pharmaceutical companies determined to be involved in a 
hugely competitive and proﬁ  table business. Now, in 2008 
medical practice and our patients have beneﬁ  ted from this 
research and development. We have a number of tools and 
options to help improve skin health and even reverse the 
adverse effects of UV light.
Skincare should be viewed as an essential part of cosmetic 
practice. We know we can efface lines using injectables, but 
if this is put against the general background of skin that is 
smooth, moist, evenly pigmented and radiant, the overall 
improvement can be dramatic. For optimum results every 
patient should be using medically approved skincare, recom-
mended by the doctor as part of a homecare program.
Essentials of skincare
Indications
The main indications for medical skincare:
• Dryness
•  Loss of elasticity
• Hyperpigmentation
• Fine  lines
•  Oily, acne prone.
Management of skincare
Lifestyle advice
We are aware patients do not want to hear advice on chang-
ing lifestyle with its consequently low chance of compliance. 
It is imperative time is taken in the consultation process to 
ensure they understand these changes are an important part 
of a skin care program and that is their responsibility. The 
doctor can make recommendations but not supervise daily 
applications of topical agents. The important factors and 
advice that need to be addressed include: sun exposure, tan 
bed usage, smoking, stress, diet, and lifestyle issues.
Product ingredients
The number of ingredients in skin products is bemusing to 
doctors yet alone our patients. Keeping it simple is best for 
all concerned. There are three main groups: cosmetics, cos-
meceuticals, and pharmaceuticals. By deﬁ  nition cosmetics 
are not, by law, able to alter the structure or function of the 
skin, so are basically limited to moisturization effects.
The term cosmeceuticals was ﬁ  rst used by Albert Kligman 
in the 1980s and comprises a growing group of agents mid 
way between cosmetics and drugs. The companies are 
reluctant to enter the extremely expensive domain of drug 
development and regulatory approval. So they are content to 
continue promoting “cosmeceutical” products that they claim 
work but are not up to drug-approved status.
To date retinoids are the only prescription-only medicines 
(POMs) available in topical products.
Alpha hydroxy acids
Alpha hydroxy acids (AHAs) are exfoliators and moisturizers 
commonly found in many different concentrations in skincare 
products. Alpha hydroxy is the name for a group of acids 
that are derived from foods, such as glycolic, lactic, maleic 
and tartaric acids, which decrease stratum corneum thick-
ness by reducing corneocyte adhesion at differing levels.4 
Histologically Ditre and colleagues showed that AHAs 
increase collagen density and mucopolysacccharides, causing 
increase in dermal thickening.5 Kligman demonstrated, by 
combining glycolic acid 8% and tretinoin 0.1%, a signiﬁ  cant 
improvement in wrinkles and skin smoothness, suggesting 
there may be some synergy between the two ingredients.6 
Medical AHA products are of higher concentration and 
acidity than over-the-counter (OTC) products. A test patch 
is advisable to exclude any sensitivities.
Retinoids
There is overwhelming evidence supporting the efﬁ  cacy and 
safety of topically applied retinoids in the treatment of pho-
todamaged skin. Tretinoin was approved as the ﬁ  rst topical 
POM in the treatment of photodamaged skin in the 1990s.3 
Epidermal effects include normalization of keratinocyte life 
cycles, decreased keratinocyte atypia and normalization of 
melanosome dispersion. Dermal changes show increased 
collagen, elastin, and glycosaminoglycan (GAGs) deposi-
tion. Visible evidence of photodamage can be signiﬁ  cantly 
improved. From a histological viewpoint structural changes 
in solar elastosis and collagen degeneration are demon-
strated with restoration of Langerhans cells and correction 
of dysplastic changes.7 Tazarotene, a retinoid analogue, has 
displayed similar effects to tretinoin.8
Patients must be thoroughly educated on the correct use 
of retinoids. A gradual increase in frequency of application is 
advised to enable tolerance to establish. Apply at night, twice 
weekly to start, increasing to every night over 4–6 weeks. 
They must expect mild redness and scaling but this subsides 
with use of additional moisturizer. The maximum effect may Clinical Interventions in Aging 2009:4 84
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take 12 months following which a maintenance regime of 
three times per week can be introduced. Retinoids should not 
be used in pregnancy. Clients will be more sun sensitive so 
concurrent use of sun protection is mandatory.
Vitamin C
Topical Vitamin C is commonly incorporated into skin 
products because of its stimulatory effect on collagen 
synthesis, its ability to regenerate vitamin E and an antioxi-
dant effect.9 It has also been found to inhibit tyrosinase and so 
reduce areas of hyperpigmentation. There is some protection 
from UV radiation and improvement in some inﬂ  ammatory 
skin conditions due to its antioxidant effects.10 The active 
form of vitamin C, L-ascorbic acid is unstable so more stable 
esteriﬁ  ed forms have been formulated. Ascorbyl palmitate 
and magnesium ascorbyl phosphate are common ingredients 
in skin care products that convert to the active form on skin 
contact. Various studies have shown some improvement in 
photodamage.11
Vitamin E
Vitamin E encompasses a family of substances with 
antioxidant and moisturizing activity. Preclinical studies 
showed topical vitamin E protects against UVB-mediated 
damage. It is commonly incorporated into cosmetic and 
cosmeceutical preparations.12
Idebenone
Derived from coenzyme q10, idebenone is a powerful 
antioxidant and is believed to stimulate the production of 
collagen. McDaniel demonstrated it to be superior in a 
comparative study to other antioxidants13 and its clinical 
effectiveness in treating photodamaged skin.14 It is effective 
in reducing wrinkles and improving the overall condition of 
the skin after prolonged use.
Moisturizers
In medical cosmetic practice, we must recommend products 
that have proven ability to improve damaged skin. Moistur-
izers on their own have limited use in skin rejuvenation and 
there is huge competition from the OTC market. A moistur-
izing sunscreen has a double beneﬁ  t and raises compliance 
levels.
Hydroquinone
Hydroquinone is a POM in the UK, but is banned OTC 
in Europe because of exogenous ochronosis, a severe 
hyperpigmenting damaging side effect. It is, however, the 
most effective depigmenting product available that inhibits 
tyrosine production. Recommended use is for 4–6 week 
periods every 12 weeks, response-dependent. Azelaic acid 
and kojic acid are alternatives.15 Kligman developed a for-
mula containing hydroquinone, retinoic acid and prednisone 
which is useful in difﬁ  cult cases but very unstable with a 
short shelf life of under four weeks.
Hormone replacement therapy
It is well documented that estrogen loss has a profound effect 
on the skin, which becomes thinner and less hydrated. In 
suitable patients, hormone replacement therapy has been 
repeatedly demonstrated to rehydrate, increase collagen 
content, elasticity and dermal thickness.16
Peptides
I mention this group of cosmeceutical agents brieﬂ  y because 
there is high public awareness due to promotion of their prod-
ucts by cosmetic companies. In particular, there are claims 
that these topical agents can produce botulinum toxin-like 
effects. There is no signiﬁ  cant evidence at this point that 
they work as anything other than moisturizers. However, 
they compose an interesting group which may have a place 
in the future.
Sunscreens
Sunscreens are essential for skin health and rejuvenation. 
Recent advances in formulations have made products easier 
to apply and more cosmetically appealing. Sunlight penetrat-
ing the Earth’s atmosphere exposes us to UVA and UVB 
ranging from 290–400 nm. Sunscreens are labeled with an 
sun protection factor (SPF) number which is only a measure 
of UVB protection. UVA has a longer wavelength than 
UVB and goes deeper into the skin, causing damage in the 
dermis. At this time there is no universally agreed method 
of labeling for UVA protection. Most products now contain 
two types of ingredients: (a) reﬂ  ective agents, for example, 
zinc oxide or titanium dioxide. They are inert, unlikely to 
cause any allergic reaction and simply reﬂ  ect the UV light; 
and (b). Chemicals that absorb and react with sunlight to 
render it harmless. Common ingredients are avobenzone, 
oxybenzone, and octyl methoxycinnamate. These cover 
most of the wavelengths but no sunscreen provides 100% 
protection. In the future, increasingly powerful antioxidants 
will be added into products so that, in theory, damage is 
repaired as it arises. To encourage compliance, moisturizers 
combined with SPF are usually recommended. Daily appli-
cation is required and not only to the face but neck, hands, 
and décolleté. Men should be reminded to cover their bare 
heads and tops of ears.Clinical Interventions in Aging 2009:4 85
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Skin rejuvenation treatments in clinic
Chemical peels
Chemical peels have been used for many years in skin 
rejuvenation. All peels are derived from basic chemicals 
known to inﬂ  ame, exfoliate, and destroy skin cells in a 
controlled manner. These effects can improve sun damage, 
solar lentigines, wrinkles, acne, melasma, and scarring. By 
peeling off the damaged cells, new ones come to the surface 
and produces a smoother, healthier-looking skin. Deeper 
peels can also induce new dermal collagen formation which 
can improve ﬁ  ne lines and wrinkles. It is essential to maintain 
the beneﬁ  ts by using medical skincare and sun protection 
throughout the year.17,18
It is easy to be confused by trade names given to peeling 
agents, but a simple classiﬁ  cation is based on their depth of 
penetration into the skin.
• Superﬁ  cial peels: glycolic acid, salicylic acid and Jessners 
solution, 10% trichloroacetic acid (TCA). These peels are 
used to treat mild sun damage, acne and melasma. They 
freshen up the skin, giving a healthy glow. A course of 
6–8 is usually recommended with maintenance sessions 
every three months. Do not expect noticeable changes 
with this type of peel, but it is safe with very limited side 
effects.
•  Medium peels: Strong Jessners solution, Resorcinol, 
15%–20% TCA, low concentration phenol. This depth of 
peel is for ﬁ  ne lines, wrinkles, mild photodamage, super-
ﬁ  cial scars and pigmentation. The skin does exfoliate and 
there is a recovery period of several days. Side effects 
include redness and occasionally increased pigmentation, 
especially in darker skin types.
•  Deep peels: Phenol, 30% TCA. Not so frequently used 
today these deep peels have mostly been replaced by 
lasers. They are used to treat deeper lines and advanced 
sun damage. There is a 2–3 week recovery time and again 
persisting redness, infection, increased pigmentation and 
scarring are possible side effects.
Chemical peels are an important tool in the treatment of a 
variety of skin conditions. It is essential that good homecare 
products and adequate skin protection be used before and 
after peels to obtain the best and long lasting results. They can 
be extremely effective in their own right as well as enhanc-
ing the beneﬁ  ts of other treatments such as botulinum toxin, 
ﬁ  llers, and cosmetic surgery.
Microdermabrasion
Microdermabrasion used to be the preserve of aestheticians, 
but systems for doctors have been introduced that allow any 
depth in the skin to be reached. The general consensus is 
that microdermabrasion is a superﬁ  cial treatment capable 
of enhancing the skin’s appearance, but does not show any 
signiﬁ  cant effect on wrinkles. There is very limited clinical 
data on microdermabrasion.19
LED light
The use of red and infrared nonlaser light has been shown to 
have beneﬁ  cial effects in skin rejuvenation, not by thermal 
damage but through photobiomodulative reactions. The vari-
ous tissue and cell types in the skin have their own absorp-
tion characteristics, absorbing light at speciﬁ  c wavelengths. 
Studies have demonstrated that selective wavelengths have 
stimulatory effects on cell types. Most importantly this has 
been demonstrated in the formation of collagen precursors 
and enzymes associated with cellular development. This tech-
nology offers a means of delivering light to treat large surface 
areas with no signiﬁ  cant adverse effects. A detailed study by 
Lee and colleagues showed signiﬁ  cant wrinkle reduction, up 
to a maximum of 36% and improvement in skin tone.20
This technology is undoubtedly an important advance 
in skin rejuvenation. There has been particular interest by 
some physicians when used as the light activating source 
in photodynamic light therapy using topical drugs such as 
5-ﬂ  uorouracil and 5 aminolevulinic acid. More investigation 
is underway to verify results and determine optimal treat-
ment regimes.21
Lasers and intense pulse light
The ﬁ  rst technologies for skin rejuvenation began in the 
early 1990s with the use of carbon dioxide lasers. These are 
powerful machines that burn off the epidermis and down 
into the reticular dermis. This enabled the skin to reform and 
appear youthful and regenerated. In the dermis, signiﬁ  cant 
changes occurred with remodeling of collagen ﬁ  bres, which 
developed up to twelve months following the treatment. 
However, the effectiveness of the technique was limited 
by discomfort during and after the procedure, a 3–4 week 
recovery period, redness and hyper- and hypopigmentation. 
The latter can appear 1–2 years post-treatment, with no 
effective treatment. Erbium-Yag lasers were then introduced 
which were marketed with reduced healing time with lower 
complication rates. However, this improvement proved to 
be minimal. All this led to a reduced demand for so called 
“ablative” laser resurfacing. A place remains for this treat-
ment, for example, in severely photodamaged or scarred 
patients, but should only be performed in specialist centers 
by experienced physicians and surgeons.Clinical Interventions in Aging 2009:4 86
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Fractional lasers
Fractional lasers treat a fraction of the skin at a time. Using 
tried and tested CO2 and Erbium-Yag and other lasers, the 
energy is delivered in fractionated columns with up to 30% 
of the skin being ablated with a single pulse. This leads to 
quicker recovery times but multiple treatment sessions are 
necessary. There are no studies yet showing how effective 
these lasers are compared to existing technology. It is not yet 
known if the trade-off of rapid recovery gives sufﬁ  ciently 
good results.
The demand for new procedures that provide optimal 
results with minimal side effects has continued to rise. 
As with many advances, another came serendipitously. 
Patients having hair removal with Nd-Yag lasers and later 
intense pulsed light (IPL) systems noticed their skin texture 
and tone improved. Histology showed some remodeling of 
collagen in the upper dermis, but not to the degree of CO2 
lasers. However, now there are many systems on the market 
claiming effects for “nonablative lasers and IPLs.” It is 
generally agreed that these machines produce subtle changes 
not always visible on photographs but with some degree of 
patient satisfaction. Claims for signiﬁ  cant wrinkle reduction 
have to be treated with scepticism.22
Radio frequency infrared technology 
for facial skin tightening
Radio frequency infrared technology for facial skin tightening 
is as yet an unproven technology with some anecdotal 
evidence for producing a degree of skin tightening by dermal 
heating and inducing collagen contraction. This can be helpful 
in reducing the appearance of jowls and nasolabial folds.23
Laser hair removal
Undoubtedly excessive facial hair can be socially isolating. 
There are many peer reviewed articles attesting to the 
effectiveness of laser/IPL hair removal systems. Preston 
and Lanigan reported high patient satisfaction rates.24 
A psychological beneﬁ  t can arise, which in itself improves 
facial appearance.
Minor surgery: Removal of lumps and bumps
Simple excision of cosmetically unacceptable lumps and 
bumps can have a surprising effect on the skin and contributes 
to the look good, feel good factor.
Dermal ﬁ  llers
Silicone injections were the early dermal ﬁ  llers but problems 
relating to permanency, granulomas and spread from site 
of injection led to its downfall. In the early 1980s, the ﬁ  rst 
temporary wrinkle filler using bovine collagen became 
accepted by physicians and the public. It was an innovative 
product but had the downside of a 3% allergic reaction 
rate. Scientists in the EU were researching hyaluronic acid 
(HA), a glycosaminoglycan which is strongly hydroscopic, 
hydrates, and adds volume to the skin. HA ﬁ  llers rapidly 
became the most popular product lines and gained Food and 
Drug Administration (FDA) approval in 2003. There have 
been attempts at introducing human-derived dermal ﬁ  llers, 
but without signiﬁ  cant success. More recently, products that 
add volume and last longer have become an important part of 
aesthetic dermatological practice, the most established being 
poly-L-lactic acid (PLLA). HA formulations and calcium 
hydroxyl appetite products are newer alternatives. Fillers 
maybe divided into categories; temporary, semipermanent, 
and permanent, line ﬁ  llers and volume enhancers. The agreed 
best practice is the use of temporary HA ﬁ  llers as line ﬁ  llers 
and PLLA or HA as volume enhancers.
Hyaluronic acid ﬁ  llers
The high allergy rate of bovine collagen provided a market 
entry for HA ﬁ  llers because of their signiﬁ  cantly reduced 
allergic response. HA is identical in all species, leading to 
high acceptability in humans.25 In addition it has been shown 
to have a longer duration.26 HA ﬁ  llers can last 6–12 months 
and in some clients the author has seen 12–24 months of 
clinical effect. This unexpectedly long duration of activity 
maybe partially explained by Wang who demonstrated that 
cross linked HA (Restylane™) stimulates collagen synthesis.27 
There are many HA products on the market, but the main 
providers are Q-Med (Uppsala, Sweden) and Allergan. The 
pros and cons of these various products are small and related 
to HA concentration and cross linking. Allergan have recently 
introduced an HA product containing lidocaine which is 
gaining popularity with patients. Pinsky and colleagues 
showed Juvederm™ to be safe and effective.28
No skin tests are necessary and treatment can, in some 
circumstances, be given at the ﬁ  rst consultation. They are 
injected into the mid dermis to ﬁ  ll nasolabial folds, marionette 
lines, chin and jowl depressions, depressed scars, lip lines, 
redeﬁ  ning lip edge, and adding lip volume.
Common side effects include erythema, redness, and 
bruising. These are short lived and resolve spontaneously 
after up to seven days. Poor injection technique, usually 
placing the material too superﬁ  cially, results in a bluish 
tinge and small nodules which can be long-lasting. This 
can be corrected by using hyaluronidase, an enzyme that Clinical Interventions in Aging 2009:4 87
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degrades HA. Delayed hypersensitivity with granulomas 
can occur in any HA products but is rare. Speciﬁ  c treatment 
protocols are recommended using local steroid injections 
and anti-inﬂ  ammatory agents.29
Volume enhancers
Poly-L-lactic acid (PLLA) is a synthetic, biodegradable inert 
peptide polymer originally used in treating facial lipoatrophy 
induced by HIV drug therapy.30 The potential in cosmetic 
use quickly became obvious, opening new possibilities in the 
nonsurgical approach to facial rejuvenation. Redeﬁ  ning malar 
prominences, softening nasolabial folds and replacing loss of 
volume in the cheeks has the potential to dramatically alter facial 
appearance. It is thought to stimulate ﬁ  broblasts laying down 
new collagen. There is therefore a gradual increase of volume.31 
Four to six sessions are usually required with maximum beneﬁ  t 
taking up to six months. Effects last 18–24 months. PLLA has 
a good safety record. Evolving protocols have reduced the inci-
dence of granulomas and nodule formation.32 The use of PLLA 
is technique-dependent and results maybe variable depending 
on patient selection and physician experience.
Q-Med and Allergan have introduced high concentration 
HA products, Sub-Q™ and Voluma™, to add facial volume. 
They have the advantage of generally only requiring one 
treatment and easy to use but the disadvantage of lasting 
approximately 12 months.
Volume enhancers have been a signiﬁ  cant nonsurgical 
advance in the treating the aging face. It is now possible to 
alter facial shape to attain a more youthful appearance. Public 
awareness is still relatively low compared to wrinkle ﬁ  llers 
but this will inevitably change.
Botulinum toxins
Botulinum toxins and Botox™ in particular revolutionized 
the nonsurgical cosmetic market since its introduction 
in late 1980s. Cosmetic use of botulinum toxin began 
when Carruthers and Carruthers coincidentally noted an 
improvement in periorbital appearance in patients undergoing 
treatment with botulinum toxin type-A for blepharospasm. 
Initial cosmetic indication was the glabellar area, but its 
use has now expanded to successfully treat a variety of 
hyperfunctional facial lines, such as peri orbital wrinkles 
(crow’s feet), lower eyelid wrinkles, nasolabial lines and 
horizontal forehead rhytides.33–35 Today, its use for treatment 
of hyperfunctional facial lines has become the most popular 
cosmetic procedure,36 with high patient satisfaction rates.37
Botox™ was licensed for cosmetic use in the US in 
April 2002 and March 2006 in the UK. There are numerous 
studies conﬁ  rming its efﬁ  cacy and safety. Dysport™ is an 
alternative Botulinum type A but with slightly different 
characteristics to Botox™ in terms of side effects and clinical 
beneﬁ  t. The most important difference is that Dysport’s™ 
effect spreads further from the site of injection.38 This can 
be particularly useful in the periorbital area but a disadvan-
tage in the forehead where brow ptsois may be a problem. 
Combining the two products can be a positive way forward. 
A Belgian study39 suggested clients previously treated with 
Botox™ are less satisﬁ  ed than with Dysport™ but further 
data is required. More botulinum products will be coming 
onto the market, which will beneﬁ  t both doctor and consumer 
in the long term.
The botulinum toxins transformed the cosmetic market 
with its simple procedure that takes 5–10 minutes and treats 
almost the whole of the face. There is extensive clinical data, 
with excellent effects and low incidence of adverse events. 
For patients it is a short, relatively pain-free, low-cost pro-
cedure with high satisfaction rates.
Phosphatidylcholine
Injecting phosphatidylcholine (PDC) has been shown to 
reduce small areas of localized or unwanted facial fat. The 
relative importance of PDC or sodium deoxycholate in pro-
ducing fat cell lysis is not yet clear. This is still a controversial 
option and needs more work. The author has used PDC in 
treating the jowls and chins since 2004 with satisfactory 
results and low incidence of side effects.40,41
Combination therapy
Unfortunately there is mainly anecdotal evidence for the 
beneﬁ  ts of combining two or more nonsurgical options. 
For example it is accepted that when treating deep glabellar 
folds optimum results are obtained using botulinum toxin 
to reduce the muscle activity and an HA ﬁ  ller to lift up the 
fold (Figure 3). The toxin can prolong the duration of the 
ﬁ  ller because mechanical force is part of the degradation 
process. This clinical beneﬁ  t was conﬁ  rmed by Carruthers 
Figure 3 Combination approach: skincare, HA ﬁ  ller, botulinum toxin after three years.Clinical Interventions in Aging 2009:4 88
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and Carruthers42 who demonstrated an increased duration of 
effect from 18 to 32 weeks.
Combination of nonsurgical and surgery is becoming 
increasingly common. Maintaining improvement post-
surgery is a logical choice (Figures 3, 4, 5).
Discussion
The introduction of increasing numbers of nonsurgical 
options for facial rejuvenation has revolutionized the 
aesthetic market. Cosmetic treatments were previously the 
sole province of the rich and famous but in the past 20 years 
the market has opened up bringing it within reach of a 
broader spectrum of the population. The public demand for 
procedures, as demonstrated in the US and UK (Figure 1) is 
clear. There has been a considerable impact of these changes 
on the public, medical and allied professions, and govern-
ments. In the UK, fuelled by the media, the public seemed 
to quickly understand and embrace the options. Newspapers, 
magazines, and radio have regular features and stories on 
various cosmetic treatments often featuring and endorsed 
by “celebrities”. In the UK, initially doctors were by and 
large uninterested and the demand was partially satiated by 
entrepreneurial nurse practitioners, aestheticians, and three 
large chains of cosmetic surgery clinics. In early 2000s a 
partial regulation of the UK market took place, governing 
the use of lasers and IPLs, which for doctors extended to 
POMs such as botulinum toxin. This government recogni-
tion stimulated an interest amongst doctors in a variety of 
specialties including family doctors, dermatologists, oph-
thalmic, general and plastic surgeons. Professional bodies, 
British Association of Plastic Surgery (BAPS) and BAAPS, 
the British Association of Cosmetic Doctors (BACD), and 
the British Association of Dermatologists (BAD) began to 
look at training as they recognized the demand for services. 
In early 2009 the BACD is launching a diploma in cosmetic 
medicine through the University of Leicester. This is a ﬁ  rst 
step by UK physicians to bring some organization and cred-
ibility to nonsurgical cosmetic medical education.
Future trends
In 2008 the UK government proposed a deregulation of 
the market. It was clear to the majority of interested parties 
that this was not in the best public interest and following a 
consultation process the proposal was withdrawn. Other EU 
member states are about to regulate, so a uniform policy 
throughout the EU would be desirable. Protection of the public 
should be a governmental priority and that means ensuring 
clinics and staff provide high quality, supervised service.
Options for professional, fully accredited cosmetic 
medical education should become increasingly available as 
the ﬁ  eld becomes recognized as a specialty.
There is an absolute necessity for more clinical studies and 
data. Botulinum toxin is the only treatment with signiﬁ  cant 
data; all the rest lag behind. The present position that allows 
suppliers to bring their products to market with minimal study 
data needs to be reassessed. There are too many commercial 
pressures demanding early market exposure. However, this 
has to alter and pressure can be brought by regulators and 
the medical profession. As new treatment options become 
available both doctors and public need the security of 
knowledge and clinical experience that the positives and 
negatives have been adequately investigated.
This is an exciting ﬁ  eld of medicine that is in its infancy and 
in a constant state of ﬂ  ux. Its growth and development needs to be 
carefully monitored by the medical profession and government.
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